Analyst Price Target is $8.38
▲ +65.84% Upside Potential
This price target is based on 3 analysts offering 12 month price targets for Catalyst Pharmaceuticals in the last 3 months. The average price target is $8.38, with a high forecast of $11.00 and a low forecast of $6.50. The average price target represents a 65.84% upside from the last price of $5.05.
Current Consensus is
The current consensus among 3 polled investment analysts is to buy stock in Catalyst Pharmaceuticals. This Buy consensus rating has held steady for over two years.
Catalyst Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases, including Lambert-Eaton myasthenic syndrome (LEMS), congenital myasthenic syndromes (CMS), MuSK antibody positive myasthenia gravis, spinal muscular atrophy (SMA) type 3, and infantile spasms. The company was founded by Huckel E. Hubert and Patrick J. McEnany in January 2002 and is headquartered in Coral Gables, FL.